Mounjaro and Erectile Dysfunction: How Weight Loss on Tirzepatide Can Improve Sexual Function

Mounjaro and erectile dysfunction may seem unrelated at first glance, yet the connection between obesity, metabolic health and sexual function is well established in medical literature. For many men living with overweight or obesity, erectile difficulties are among the most distressing consequences of excess weight. Furthermore, a growing body of clinical evidence now shows that tirzepatide can help reverse the metabolic drivers of ED, offering a genuine improvement in sexual health alongside significant weight loss.

At CutKilo, our doctor-led team at 86 Harley Street sees this pattern regularly. Male patients who begin Mounjaro treatment for weight loss often report improvements in confidence, energy and intimate relationships within the first few months. In this article, we explain why obesity causes erectile dysfunction, what the latest clinical evidence says about tirzepatide and sexual function, and what you can realistically expect during treatment.

Yes, for many men. Erectile dysfunction linked to obesity typically results from endothelial dysfunction, low testosterone and chronic inflammation. Mounjaro (tirzepatide) addresses these root causes through meaningful weight loss. In a 2025 clinical study published in Reproductive Biology and Endocrinology, men treated with tirzepatide showed greater improvements in erectile function than those receiving testosterone replacement therapy (TRT). However, Mounjaro is not licensed as an ED treatment. Its benefits for sexual function are a secondary effect of metabolic improvement and weight reduction.

Erectile function depends on healthy blood flow, adequate hormone levels and intact nerve signalling. Obesity disrupts all three pathways. Men with a BMI above 30 have a 70 to 96 per cent higher probability of developing ED compared with men at a healthy weight, according to a 2023 systematic review in the Journal of Clinical Medicine.

The mechanisms are well characterised. Excess visceral fat promotes chronic low-grade inflammation and oxidative stress, which damage the endothelium (the lining of blood vessels). Healthy erections require the endothelium to release nitric oxide, a signalling molecule that relaxes smooth muscle in the penile arteries. When endothelial function is impaired, blood flow to the penis is reduced and erections become difficult to achieve or maintain.

In addition, adipose tissue converts testosterone to oestradiol via the enzyme aromatase. The more body fat a man carries, the more testosterone is converted, leading to a state known as functional or metabolic hypogonadism. Low testosterone further reduces libido, energy and the neurological drive behind arousal. Consequently, obesity creates a vicious cycle: excess fat lowers testosterone, which reduces motivation for physical activity, which promotes further weight gain.

A landmark study presented at ENDO 2025, the Endocrine Society Annual Meeting, compared three approaches in 83 men with obesity, functional hypogonadism and insulin resistance. Participants were assigned to tirzepatide plus lifestyle changes, transdermal testosterone replacement plus lifestyle changes, or lifestyle changes alone.

After two months, the tirzepatide group outperformed both comparators on every measured outcome. Specifically, men taking tirzepatide experienced greater reductions in body weight, waist circumference and fat mass. They also showed significantly greater improvements in both free testosterone and total testosterone levels. Most notably, erectile function scores improved more in the tirzepatide group than in men receiving TRT directly.

This finding is clinically important. Unlike TRT, which suppresses the hypothalamic-pituitary-gonadal axis (meaning the body reduces its own testosterone production in response to the external supply), tirzepatide appears to restore endogenous hormone production by removing the metabolic interference caused by excess adiposity. In other words, tirzepatide helps the body produce its own testosterone again rather than replacing it artificially. For a deeper look at the hormonal effects of treatment, see our guide on Mounjaro and testosterone.

Clinical evidence suggests that a weight reduction of 5 to 10 per cent of total body weight is often sufficient to produce measurable improvements in erectile function. A meta-analysis of randomised controlled trials confirmed that men with overweight or obesity who lost weight showed statistically significant improvements in erectile function compared with control groups.

In the SURMOUNT-1 trial, participants receiving the highest dose of tirzepatide (15 mg) lost an average of 22.5 per cent of their body weight over 72 weeks. Even at the lower 5 mg dose, average weight loss exceeded 15 per cent. These figures are well above the 5 to 10 per cent threshold associated with ED improvement, which means that most men on Mounjaro can expect to reach a clinically meaningful level of weight loss within the first few months of treatment.

It is worth noting that improvements in erectile function are not instantaneous. As with other metabolic benefits of weight loss, sexual health typically improves gradually. Many patients notice changes from around month two or three, with continued improvement as weight loss progresses and hormonal balance is restored.

Tirzepatide’s benefits for erectile function likely extend beyond simple calorie reduction. GLP-1 and GIP receptor agonists have demonstrated anti-inflammatory properties independent of weight loss. Tirzepatide reduces levels of C-reactive protein (CRP), a key marker of systemic inflammation, and improves insulin sensitivity.

Since endothelial dysfunction is driven in large part by chronic inflammation and insulin resistance, these additional pharmacological effects may contribute to improved blood vessel health. In particular, reduced inflammation in the vascular endothelium supports greater nitric oxide bioavailability, which is the fundamental mechanism behind healthy erectile responses.

Additionally, improved insulin sensitivity reduces the metabolic stress on the cardiovascular system as a whole. Better heart health and improved peripheral blood flow both support erectile function. For men with coexisting type 2 diabetes, this dual benefit of glycaemic control and weight loss is especially relevant.

Phosphodiesterase type 5 (PDE5) inhibitors such as sildenafil (Viagra) and tadalafil (Cialis) remain the first-line pharmacological treatment for erectile dysfunction. These medications work by enhancing the effect of nitric oxide in the penile vasculature, producing erections on demand. They are effective, well studied and generally safe.

However, PDE5 inhibitors treat the symptom rather than the cause. They do not address the underlying endothelial dysfunction, hormonal imbalance or insulin resistance that drives ED in men with obesity. For this reason, many clinicians now view weight management as a complementary strategy alongside ED medication.

Mounjaro is not a replacement for Viagra or Cialis, and it is not licensed for the treatment of erectile dysfunction. Nevertheless, men who achieve significant weight loss on tirzepatide may find that their need for PDE5 inhibitors decreases or that these medications become more effective. Some men are able to discontinue ED medication entirely once metabolic health improves, although this should always be discussed with a prescribing doctor.

Erectile dysfunction can have causes beyond obesity, including cardiovascular disease, neurological conditions, medication side effects and psychological factors. If you are experiencing persistent ED, it is important to have a thorough medical assessment before attributing the problem solely to weight.

Conversely, ED in a man with obesity is often an early warning sign of cardiovascular disease. The penile arteries are smaller than coronary arteries and tend to show the effects of endothelial dysfunction earlier. In clinical practice, new-onset ED in a man over 40 with a raised BMI warrants cardiovascular screening, including blood pressure, lipid profile and HbA1c.

At CutKilo, we routinely assess cardiovascular risk as part of our initial consultation. If you are considering Mounjaro for weight loss and are also experiencing erectile difficulties, our doctors can advise on how treatment may benefit both your weight and your sexual health within a supervised medical framework.

Does Mounjaro cause erectile dysfunction? No. Erectile dysfunction is not listed as a side effect of tirzepatide in the MHRA Summary of Product Characteristics or the SURMOUNT clinical trial data. In fact, the weight loss and metabolic improvements associated with Mounjaro are more likely to improve rather than worsen erectile function.

How quickly will erectile function improve on Mounjaro? Most men begin to notice improvements from around month two or three, once meaningful weight loss has occurred and testosterone levels start to recover. The full benefit may take six months or longer, as hormonal rebalancing is a gradual process.

Can I take Mounjaro and Viagra at the same time? Generally, yes. There is no known pharmacological interaction between tirzepatide and PDE5 inhibitors such as sildenafil or tadalafil. However, both Mounjaro and PDE5 inhibitors can lower blood pressure, so your doctor should be aware of all medications you are taking.

Will erectile function return to normal after losing weight on Mounjaro? For many men whose ED is primarily driven by obesity and metabolic dysfunction, significant weight loss can restore normal or near-normal erectile function. However, outcomes depend on age, duration of obesity, severity of vascular damage and other individual factors. Some men may still benefit from ED medication alongside weight management.

Is Mounjaro suitable for men who are not overweight but have ED? No. Mounjaro is licensed for weight management in adults with a BMI of 30 or above, or 27 or above with at least one weight-related comorbidity. It is not appropriate as a standalone treatment for erectile dysfunction in men at a healthy weight.

Erectile dysfunction in men with obesity is overwhelmingly a metabolic problem, driven by endothelial damage, low testosterone and chronic inflammation. Mounjaro addresses all three of these root causes through sustained, clinically significant weight loss. A 2025 study found that tirzepatide outperformed testosterone replacement therapy for restoring both hormone levels and erectile function in men with metabolic hypogonadism, offering a treatment approach that works with the body’s own physiology rather than against it.

If you are living with overweight or obesity and experiencing erectile difficulties, weight loss is one of the most effective steps you can take. Mounjaro is not an ED drug, but for many men, the metabolic transformation it enables can lead to meaningful improvements in sexual health, confidence and quality of life.